A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the
treatment of Fragile X Syndrome in adolescent and adult males.